AAPL345.36-1.74 (-0.50%) ▼|ABBV287.64+1.25 (+0.44%) ▲|ABT103.21+0.11 (+0.11%) ▲|ACN245.06+9.90 (+4.21%) ▲|ADBE247.73-0.64 (-0.26%) ▼|AMAT413.18+17.25 (+4.36%) ▲|AMD566.94+6.68 (+1.19%) ▲|AMGN449.95+2.00 (+0.45%) ▲|AMT177.77-6.07 (-3.30%) ▼|AMZN252.54-0.56 (-0.22%) ▼|AVGO347.23+4.90 (+1.43%) ▲|AXP316.12+3.21 (+1.02%) ▲|BA166.71-1.47 (-0.87%) ▼|BAC51.08+0.40 (+0.79%) ▲|BKNG148.00-2.15 (-1.43%) ▼|BLK1,150.65+14.60 (+1.29%) ▲|BMY60.42-1.13 (-1.84%) ▼|BNY148.96+1.38 (+0.94%) ▲|BRK-B544.11+1.12 (+0.21%) ▲|C124.09+1.40 (+1.14%) ▲|CAT715.96+2.65 (+0.37%) ▲|CL91.91-0.26 (-0.28%) ▼|CMCSA21.68-0.17 (-0.76%) ▼|COF204.41+0.97 (+0.47%) ▲|COP150.26+2.30 (+1.55%) ▲|COST983.47-8.67 (-0.87%) ▼|CRM240.71-0.18 (-0.07%) ▼|CSCO109.93-1.45 (-1.30%) ▼|CVS90.66-0.47 (-0.52%) ▼|CVX231.27+3.04 (+1.33%) ▲|DE640.21+0.63 (+0.10%) ▲|DHR234.37+2.37 (+1.02%) ▲|DIS109.14-1.09 (-0.99%) ▼|DUK124.73-0.07 (-0.06%) ▼|EMR167.49+1.22 (+0.73%) ▲|FDX301.65-5.45 (-1.77%) ▼|GD354.34-0.55 (-0.16%) ▼|GE303.32+5.66 (+1.90%) ▲|GEV890.28-4.80 (-0.54%) ▼|GILD159.23+0.15 (+0.09%) ▲|GM81.11+0.57 (+0.71%) ▲|GOOG320.44+3.61 (+1.14%) ▲|GOOGL323.80+3.22 (+1.00%) ▲|GS923.33+11.56 (+1.27%) ▲|HD318.52+0.02 (+0.01%) ▲|HON219.28+0.47 (+0.21%) ▲|IBM251.45+1.20 (+0.48%) ▲|INTC93.80+0.06 (+0.06%) ▲|INTU330.13+1.68 (+0.51%) ▲|ISRG447.28+1.40 (+0.31%) ▲|JNJ270.25+1.52 (+0.57%) ▲|JPM339.65+3.86 (+1.15%) ▲|KO91.83+0.65 (+0.71%) ▲|LIN508.40-0.25 (-0.05%) ▼|LLY1,286.30+4.39 (+0.34%) ▲|LMT629.32+6.33 (+1.02%) ▲|LOW198.75+0.57 (+0.29%) ▲|LRCX254.12+13.27 (+5.51%) ▲|MA613.49+3.64 (+0.60%) ▲|MCD251.60+2.13 (+0.85%) ▲|MDLZ61.87-0.48 (-0.77%) ▼|MDT94.87+0.92 (+0.98%) ▲|META613.34-6.85 (-1.10%) ▼|MMM172.23+0.65 (+0.38%) ▲|MO73.48-0.01 (-0.01%) ▼|MRK140.34-1.49 (-1.05%) ▼|MS189.48+2.57 (+1.38%) ▲|MSFT528.46-2.88 (-0.54%) ▼|MU972.96+44.20 (+4.76%) ▲|NEE81.95-0.47 (-0.57%) ▼|NFLX61.76-0.76 (-1.22%) ▼|NKE37.26-0.30 (-0.80%) ▼|NOW150.63-4.15 (-2.68%) ▼|NVDA217.08-0.87 (-0.40%) ▼|ORCL130.98+0.45 (+0.34%) ▲|PEP132.30-1.20 (-0.90%) ▼|PFE29.38-0.43 (-1.43%) ▼|PG159.22-0.01 (-0.01%) ▼|PLTR194.37-4.36 (-2.19%) ▼|PM202.89+0.27 (+0.13%) ▲|QCOM181.52-2.66 (-1.44%) ▼|RTX197.12+2.52 (+1.30%) ▲|SBUX104.33+1.29 (+1.25%) ▲|SCHW88.86-0.44 (-0.49%) ▼|SO92.58-0.07 (-0.08%) ▼|SPG212.19-0.10 (-0.04%) ▼|T21.04+0.10 (+0.45%) ▲|TMO700.50+7.48 (+1.08%) ▲|TMUS146.74-0.09 (-0.06%) ▼|TSLA401.00-6.46 (-1.59%) ▼|TXN305.50-3.41 (-1.10%) ▼|UBER65.57-0.21 (-0.32%) ▼|UNH412.43+2.04 (+0.50%) ▲|UNP301.70+1.82 (+0.61%) ▲|UPS104.89-1.20 (-1.13%) ▼|USB59.65-0.10 (-0.16%) ▼|V401.72-0.15 (-0.04%) ▼|VZ43.76-0.18 (-0.40%) ▼|WFC84.38+1.72 (+2.07%) ▲|WMT118.74-0.58 (-0.49%) ▼|XOM183.42+3.51 (+1.95%) ▲|AAPL345.36-1.74 (-0.50%) ▼|ABBV287.64+1.25 (+0.44%) ▲|ABT103.21+0.11 (+0.11%) ▲|ACN245.06+9.90 (+4.21%) ▲|ADBE247.73-0.64 (-0.26%) ▼|AMAT413.18+17.25 (+4.36%) ▲|AMD566.94+6.68 (+1.19%) ▲|AMGN449.95+2.00 (+0.45%) ▲|AMT177.77-6.07 (-3.30%) ▼|AMZN252.54-0.56 (-0.22%) ▼|AVGO347.23+4.90 (+1.43%) ▲|AXP316.12+3.21 (+1.02%) ▲|BA166.71-1.47 (-0.87%) ▼|BAC51.08+0.40 (+0.79%) ▲|BKNG148.00-2.15 (-1.43%) ▼|BLK1,150.65+14.60 (+1.29%) ▲|BMY60.42-1.13 (-1.84%) ▼|BNY148.96+1.38 (+0.94%) ▲|BRK-B544.11+1.12 (+0.21%) ▲|C124.09+1.40 (+1.14%) ▲|CAT715.96+2.65 (+0.37%) ▲|CL91.91-0.26 (-0.28%) ▼|CMCSA21.68-0.17 (-0.76%) ▼|COF204.41+0.97 (+0.47%) ▲|COP150.26+2.30 (+1.55%) ▲|COST983.47-8.67 (-0.87%) ▼|CRM240.71-0.18 (-0.07%) ▼|CSCO109.93-1.45 (-1.30%) ▼|CVS90.66-0.47 (-0.52%) ▼|CVX231.27+3.04 (+1.33%) ▲|DE640.21+0.63 (+0.10%) ▲|DHR234.37+2.37 (+1.02%) ▲|DIS109.14-1.09 (-0.99%) ▼|DUK124.73-0.07 (-0.06%) ▼|EMR167.49+1.22 (+0.73%) ▲|FDX301.65-5.45 (-1.77%) ▼|GD354.34-0.55 (-0.16%) ▼|GE303.32+5.66 (+1.90%) ▲|GEV890.28-4.80 (-0.54%) ▼|GILD159.23+0.15 (+0.09%) ▲|GM81.11+0.57 (+0.71%) ▲|GOOG320.44+3.61 (+1.14%) ▲|GOOGL323.80+3.22 (+1.00%) ▲|GS923.33+11.56 (+1.27%) ▲|HD318.52+0.02 (+0.01%) ▲|HON219.28+0.47 (+0.21%) ▲|IBM251.45+1.20 (+0.48%) ▲|INTC93.80+0.06 (+0.06%) ▲|INTU330.13+1.68 (+0.51%) ▲|ISRG447.28+1.40 (+0.31%) ▲|JNJ270.25+1.52 (+0.57%) ▲|JPM339.65+3.86 (+1.15%) ▲|KO91.83+0.65 (+0.71%) ▲|LIN508.40-0.25 (-0.05%) ▼|LLY1,286.30+4.39 (+0.34%) ▲|LMT629.32+6.33 (+1.02%) ▲|LOW198.75+0.57 (+0.29%) ▲|LRCX254.12+13.27 (+5.51%) ▲|MA613.49+3.64 (+0.60%) ▲|MCD251.60+2.13 (+0.85%) ▲|MDLZ61.87-0.48 (-0.77%) ▼|MDT94.87+0.92 (+0.98%) ▲|META613.34-6.85 (-1.10%) ▼|MMM172.23+0.65 (+0.38%) ▲|MO73.48-0.01 (-0.01%) ▼|MRK140.34-1.49 (-1.05%) ▼|MS189.48+2.57 (+1.38%) ▲|MSFT528.46-2.88 (-0.54%) ▼|MU972.96+44.20 (+4.76%) ▲|NEE81.95-0.47 (-0.57%) ▼|NFLX61.76-0.76 (-1.22%) ▼|NKE37.26-0.30 (-0.80%) ▼|NOW150.63-4.15 (-2.68%) ▼|NVDA217.08-0.87 (-0.40%) ▼|ORCL130.98+0.45 (+0.34%) ▲|PEP132.30-1.20 (-0.90%) ▼|PFE29.38-0.43 (-1.43%) ▼|PG159.22-0.01 (-0.01%) ▼|PLTR194.37-4.36 (-2.19%) ▼|PM202.89+0.27 (+0.13%) ▲|QCOM181.52-2.66 (-1.44%) ▼|RTX197.12+2.52 (+1.30%) ▲|SBUX104.33+1.29 (+1.25%) ▲|SCHW88.86-0.44 (-0.49%) ▼|SO92.58-0.07 (-0.08%) ▼|SPG212.19-0.10 (-0.04%) ▼|T21.04+0.10 (+0.45%) ▲|TMO700.50+7.48 (+1.08%) ▲|TMUS146.74-0.09 (-0.06%) ▼|TSLA401.00-6.46 (-1.59%) ▼|TXN305.50-3.41 (-1.10%) ▼|UBER65.57-0.21 (-0.32%) ▼|UNH412.43+2.04 (+0.50%) ▲|UNP301.70+1.82 (+0.61%) ▲|UPS104.89-1.20 (-1.13%) ▼|USB59.65-0.10 (-0.16%) ▼|V401.72-0.15 (-0.04%) ▼|VZ43.76-0.18 (-0.40%) ▼|WFC84.38+1.72 (+2.07%) ▲|WMT118.74-0.58 (-0.49%) ▼|XOM183.42+3.51 (+1.95%) ▲|
13.7 C
New York
Wednesday, October 28, 2026

Tag: protein

newsFORsourcecompanycontentinformation1releasesmarket

CancerVax Targets Liver Cancers to Further Showcase Flexibility of Its Universal Platform

Using AI machine learning, the Company discovers distinct biomarkers for detecting certain rare liver cancers that have stem cell characteristics and will include them as additional indications in its preclinical program 
Using AI machine learning, the Company discovers distinct biomarkers for detecting certain rare liver cancers that have stem cell characteristics and will include them as additional indications in its preclinical program

AB Science announces EMA approval of Masivet shelf-life extension to 4 years

PRESS RELEASE

Where the Sea Meets the Skin: Shapellx Unveils Innovative New OceanHug™ Collection Made from Oyster Shells

The new sustainable, ocean-inspired collection enhances body contours while delivering the perfect balance of style, comfort, and sustainability.

NSCEB Announces Biotech Across America Roadshow, Makes First Stop in North Carolina

NSCEB is launching a 3-month tour of the booming U.S. biotechnology ecosystem  RALEIGH, N.C., June 6, 2025 /PRNewswire/ -- Yesterday, NSCEB Vice Chair Michelle Rozo...

Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference

LEXINGTON, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros’ Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 9:20 a.m. Eastern time.

StarKist® Partners with Feed the Children and Cornerstones for Fourth Annual Summer Food and Resource Rally in Northern Virginia

Hundreds of Families Receive Food and Household Essentials at Resource Rally RESTON, Va., June 6, 2025 /PRNewswire/ -- Hunger remains a significant issue in communities throughout...

Jack Link’s Marks 40th Anniversary with “Christmas for Carnivores” Promotion to Celebrate National Jerky Day, June 12

The company is celebrating 40 years of protein snacking with a special 50% discount on a gift box of Jack Link's beef jerky, only...

Sionna Therapeutics Announces Presentation of Preclinical Data that Demonstrate Proprietary Dual Combination Therapies Enable Full CFTR Correction in CFHBE Model

Data featured in oral presentation and poster session at 48th European Cystic Fibrosis Conference

Sobi and Apellis: Aspaveli®/Empaveli® Demonstrates Sustained One-Year Efficacy in Phase 3 Study for Rare Kidney Diseases

STOCKHOLM, June 6, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) and Apellis Pharmaceuticals, Inc. today presented new data from the open-label period of the Phase...

Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN

WALTHAM, Mass. and STOCKHOLM, June 06, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® (STO:SOBI) today presented new data from the open-label period of the Phase 3 VALIANT study, investigating EMPAVELI® (pegcetacoplan) for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). The data were presented as part of a late-breaking session at the European Renal Association (ERA) Congress.

Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer

– This submission is supported by the pivotal Phase 3 VERITAC-2 clinical trial, results of which were recently presented at the 2025 American Society for Clinical Oncology Annual Meeting and published in The New England Journal of Medicine –

Meala Partners with dsm-firmenich to Commercialize Texturizing Protein for Meat Alternatives

PB Pea protein, a high-performance texturizer is ready for market release in Europe, bringing cleaner labels and better nutritional value to meat alternatives HAIFA, Israel,...

Rectify Pharma Presents Translational Data Demonstrating Improvements in Kidney Function and Reductions in Vascular Calcification at ERA 2025

Potent, selective ABCC6-targeting positive functional modulator (PFM) improved multiple markers of renal function in animal models of chronic kidney disease (CKD)

GenEditBio Announces First Patient Dosed in Investigator-Initiated Trial of GEB‑101, World’s First In Vivo CRISPR-Cas Ribonucleoprotein-Based Genome Editing Investigational Therapy for TGFBI Corneal Dystrophy

HONG KONG, BEIJING and BOSTON, June 6, 2025 /PRNewswire/ -- GenEditBio Limited ("GenEditBio"), a clinical-stage biotechnology start-up company focusing on genome editing therapeutic solutions...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsProtein

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers